Ness Therapeutics Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
Ness Therapeutics General Information
Description
Operator of a biotechnology company intended to protect from all respiratory virus infections. The company aims to disrupt conventional methods such as vaccines and pathogen-targeted therapeutics by drawing inspiration from the innate immune system, enabling the healthcare industry to establish a virus-agnostic strategy to block transmission from infected individuals.
Contact Information
Website
www.nesstherapeuticsinc.com(Operating Subsidiary)
Corporate Office
- MaRS Discovery District
- Toronto, Ontario M5G 1L7
- Canada
Corporate Office
- MaRS Discovery District
- Toronto, Ontario M5G 1L7
- Canada
Ness Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 04-Mar-2024 | Completed | Clinical Trials - Phase 3 | |||
| 1. Seed Round | 29-Apr-2021 | Completed | Startup |
Ness Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Ness Therapeutics Patents
Ness Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025517026-A | Ptpn2 inhibitors | Active | 13-May-2022 | ||
| WO-2023220572-A1 | Ptpn2 inhibitors | Inactive | 13-May-2022 | ||
| WO-2022261145-A1 | Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes | Inactive | 10-Jun-2021 | C07D285/10 |
Ness Therapeutics Signals
Ness Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioGeneration Ventures | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| i2020 Accelerator | Accelerator/Incubator | Minority |
Ness Therapeutics FAQs
-
When was Ness Therapeutics founded?
Ness Therapeutics was founded in 2020.
-
Where is Ness Therapeutics headquartered?
Ness Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Ness Therapeutics?
Ness Therapeutics has 3 total employees.
-
What industry is Ness Therapeutics in?
Ness Therapeutics’s primary industry is Biotechnology.
-
Is Ness Therapeutics a private or public company?
Ness Therapeutics is a Private company.
-
What is Ness Therapeutics’s current revenue?
The current revenue for Ness Therapeutics is .
-
How much funding has Ness Therapeutics raised over time?
Ness Therapeutics has raised $7.5M.
-
Who are Ness Therapeutics’s investors?
BioGeneration Ventures, OrbiMed, and i2020 Accelerator have invested in Ness Therapeutics.
-
When was Ness Therapeutics acquired?
Ness Therapeutics was acquired on 04-Mar-2024.
-
Who acquired Ness Therapeutics?
Ness Therapeutics was acquired by Eilean Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process